Conaghan, P. G., Katz, N., Hunter, D., Guermazi, A., Hochberg, M., Somberg, K., … Goel, N. (2023). POS1348 EFFECTS OF SPRIFERMIN ON A NOVEL OUTCOME OF OSTEOARTHRITIS SYMPTOM PROGRESSION: POST-HOC ANALYSIS OF THE FORWARD RANDOMIZED TRIAL. In Annals of the Rheumatic Diseases (Vol. 82, pp. 1025–1026). Elsevier BV. https://doi.org/10.1136/annrheumdis-2023-eular.2454

Conaghan, P. G., N. Katz, D. Hunter, A. Guermazi, M. Hochberg, K. Somberg, J. Clive, M. Johnson, and N. Goel. “POS1348 EFFECTS OF SPRIFERMIN ON A NOVEL OUTCOME OF OSTEOARTHRITIS SYMPTOM PROGRESSION: POST-HOC ANALYSIS OF THE FORWARD RANDOMIZED TRIAL.” In Annals of the Rheumatic Diseases, 82:1025–26. Elsevier BV, 2023. https://doi.org/10.1136/annrheumdis-2023-eular.2454.

Conaghan PG, Katz N, Hunter D, Guermazi A, Hochberg M, Somberg K, et al. POS1348 EFFECTS OF SPRIFERMIN ON A NOVEL OUTCOME OF OSTEOARTHRITIS SYMPTOM PROGRESSION: POST-HOC ANALYSIS OF THE FORWARD RANDOMIZED TRIAL. In: Annals of the Rheumatic Diseases. Elsevier BV; 2023. p. 1025–6.

Conaghan, P. G., et al. “POS1348 EFFECTS OF SPRIFERMIN ON A NOVEL OUTCOME OF OSTEOARTHRITIS SYMPTOM PROGRESSION: POST-HOC ANALYSIS OF THE FORWARD RANDOMIZED TRIAL.” Annals of the Rheumatic Diseases, vol. 82, Elsevier BV, 2023, pp. 1025–26. Crossref, doi:10.1136/annrheumdis-2023-eular.2454.

Conaghan PG, Katz N, Hunter D, Guermazi A, Hochberg M, Somberg K, Clive J, Johnson M, Goel N. POS1348 EFFECTS OF SPRIFERMIN ON A NOVEL OUTCOME OF OSTEOARTHRITIS SYMPTOM PROGRESSION: POST-HOC ANALYSIS OF THE FORWARD RANDOMIZED TRIAL. Annals of the Rheumatic Diseases. Elsevier BV; 2023. p. 1025–1026.